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Abstract
Staphylococcal necrotizing pneumonia (NP) is a severe disease associated with Panton–Valentine leucocidin (PVL). NP was initially
described for methicillin-susceptible Staphylococcus aureus (MSSA) infection, but cases associated with methicillin-resistant S. aureus
(MRSA) infection have increased concomitantly with the incidence of community-acquired MRSA worldwide. The role of methicillin
resistance in the severity of NP remains controversial. The characteristics and outcomes of 133 patients with PVL-positive S. aureus
community-acquired pneumonia (CAP) were compared according to methicillin resistance. Data from patients hospitalized for PVL-posi-
tive S. aureus CAP in France from 1986 to 2010 were reported to the National Reference Centre for Staphylococci and were included
in the study. The primary end point was mortality. Multivariate logistic modelling and the Cox regression were used for subsequent
analyses. We analysed 29 cases of PVL-MRSA and 104 cases of PVL-MSSA pneumonia. Airway haemorrhages were more frequently
associated with PVL-MSSA pneumonia. However, no differences in the initial severity or the management were found between these
two types of pneumonia. The rate of lethality was 39% regardless of methicillin resistance. By Cox regression analysis, methicillin resis-
tance was not found to be a signiﬁcant independent predictor of mortality at 7 or 30 days (p 0.65 and p 0.71, respectively). Our study
demonstrates that methicillin resistance is not associated with the severity of staphylococcal necrotizing pneumonia.
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Introduction
Necrotizing pneumonia (NP) due to infection with Staphylo-
coccus aureus was described in a study by Gillet et al. [1] in
2002, and numerous cases have since been reported world-
wide [2–5]. The disease is characterized by rapidly progress-
ing and extensive bilateral pneumonia. The overall mortality
rate ranges from 30% to 75% [1,2] and death occurs rapidly
with a median survival time between 4 and 10 days [1,2].
Erythroderma, airway bleeding and leukopenia are predictive
of mortality [6,7]. NP is associated with the production of
Panton–Valentine leucocidin (PVL), an otherwise infrequently
encountered virulence factor produced by S. aureus. Initially,
cases of NP were primarily due to PVL-positive, methicillin-
susceptible S. aureus (PVL-MSSA) [8]. However, since 2000,
NP caused by PVL-positive, community-acquired (CA) methi-
cillin-resistant S. aureus (PVL-MRSA) has been reported
worldwide [9–12].
The prevalence of CA-MRSA varies considerably by coun-
try [11] and has increased over time. In the ﬁrst series of
NP cases published in 2002, only one out of 16 cases was
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due to PVL-MRSA [1], whereas PVL-MRSA accounted for
12% of a series of 50 cases collected from 2002 to 2005 [6].
Community-acquired MRSA pneumonia (mostly caused by
PVL-MRSA) is reportedly a severe disease, as an American
study from the Centers for Disease Control and Prevention
found fatality rates as high as 60% [13]. Therefore, focus has
recently shifted to the MRSA strains that cause community-
acquired pneumonia (CAP) and, speciﬁcally, to whether the
resistance proﬁle of CA-MRSA increases the severity
[10,12,14–16]. This question remains unresolved, as there
have been no prospective studies that have compared the
characteristics and outcomes of PVL-MRSA and PVL-MSSA
NP cases.
From 1986 to 2010, 161 cases of CAP caused by PVL-
positive S. aureus were collected in France. In this study, we
compared the characteristics and outcomes for 104 cases of
PVL-MSSA with 29 cases of PVL-MRSA.
Patients and Methods
Since 1986, case reports of CAP caused by strains of S. aur-
eus have been collected by the French National Reference
Centre for Staphylococci (Lyon, France) [1]. For cases with
isolates harbouring the PVL genes, a standardized data form
was completed.
Deﬁnitions
Community-acquired pneumonia was deﬁned by symptoms
of a lower respiratory tract infection (cough, expectoration
and chest pain), by pulmonary inﬁltrates on chest radio-
graphs that were not attributable to other causes and by the
lack of the following healthcare risk factors: recent hospital-
ization, dialysis or residence in a long-term care facility.
Staphylococcus aureus CAP was deﬁned by isolation of S. aur-
eus within 48 h of hospital admission. Isolations were per-
formed using one of the following procedures: (i) puncture
of a pleural effusion or lung abscess; (ii) culture from bronc-
hoalveolar lavage ﬂuid (104 CFU/mL), Wimberley brushing
(103 CFU/mL) or protected tracheal aspiration (103 CFU/
mL); or (iii) blood culture revealing S. aureus as the only rele-
vant pathogen.
Microbiological studies
Staphylococcus aureus isolates were tested for toxin genes
and antimicrobial susceptibility by the French National Refer-
ence Centre for Staphylococci. Genes encoding PVL were
detected using PCR-based methods [17]. Isolates were
tested for susceptibility by broth microdilution using the
interpretive criteria of the CLSI [18]. In addition, the mecA
gene, which codes for methicillin resistance, was detected by
PCR for each isolate [19].
Study design and population
This study was a nested case–control study of a prospective
cohort of patients hospitalized for S. aureus CAP. Only cases
caused by PVL-positive strains were included. A case was
deﬁned as a patient with PVL-MRSA CAP, and a control was
a patient with PVL-MSSA CAP.
Each of the 161 cases included were examined for tempo-
ral changes. Analyses comparing PVL-MRSA and PVL-MSSA
were thereafter restricted to those 133 cases with complete
data.
Data collection
The following information was collected: demographic data,
medical history, signs and symptoms of infection, disease
course, radiological and laboratory results from the ﬁrst
48 h of hospitalization, and the time at which antimicrobial
agents active against S. aureus were used. The possible out-
comes were life or death at discharge. Severity was rated
using the Paediatric Risk of Mortality score (PRISM) for
patients less than 18 years old, and the Simpliﬁed Acute
Physiology Score II (SAPS II) for adult patients. A patient
with a severity score above the 75th centile or admitted to
the intensive-care unit (ICU) was classiﬁed as severe.
Statistical analysis
Annual data were clustered into three periods for which
MSSA cases were equally distributed. Increasing trends for
the time of observed incidence of reported cases of PVL-
positive CA-MRSA NP were examined using a chi-square
test (for linear trends) and Poisson regression analysis.
The clinical and biological features were compared using
the Pearson’s chi-square test or Fisher’s exact test (for cate-
gorical variables) and the Student’s t test or the Mann–Whit-
ney U test (for continuous variables).
To identify risk factors associated with PVL-MRSA, multi-
variate logistic regression was performed using a threshold
of 0.20 for inclusion into the model. The model’s goodness
of ﬁt was assessed with the Hosmer–Lemeshow test.
Survival probability was estimated using the Kaplan–Meier
method. The baseline was deﬁned as the day of admission
and patients who survived were followed up upon discharge.
If patients died within 24 h of admission, the observation
period was rounded to 0.5 days. The differences in 7-day
and 30-day cumulative survival distributions of survivors and
non-survivors were assessed by log-rank tests. Potential fac-
tors associated with survival were examined by a Cox pro-
portional hazards regression analysis. Proportional hazard
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assumptions and the interactions between prognostic factors
and time were tested.
For all tests performed, a two-tailed p value <0.05 was
considered statistically signiﬁcant. Analyses were performed
with SPSS 17.0 software (SPPS Inc., Chicago, IL, USA).
Results
In all, 161 cases of PVL-positive S. aureus CAP were identi-
ﬁed; 124 of these cases were PVL-MSSA (77%) and 37 were
PVL-MRSA (23%). Each of these cases was considered for
the trend analysis of the proportion of MRSA, but 28 cases
were excluded from further analysis because of missing data.
Incidence of reported cases
The number of patients with PVL-positive CA-MRSA CAP
increased from ﬁve cases (10.9%) before 2004 to 14 cases
(25.5%) between 2005 and 2007, and reached 18 cases (30%)
after 2008 (p 0.024).
Demographic conditions and medical history
In total, 104 PVL-MSSA cases and 29 PVL-MRSA cases were
analysed (Table 1). The median age of CA-MSSA patients was
22 years, and that of CA-MRSA patients was 22.5 years
(p 0.717). Most patients had no underlying conditions (88.5% or
75.9% for PVL-MSSA and PVL-MRSA cases, respectively,
p 0.129). The symptoms that occurred before hospitalization
were similar, as the percentages of patients with preceding inﬂu-
enza-like symptoms were 59.8% and 65.5% (p 0.669) in PVL-
MSSA and PVL-MRSA cases, respectively, and those with pre-
existing skin and soft-tissue infections were 26.9% and 10.3%
(p 0.082). There was no clear seasonal trend but 33.8% of all
cases occurred during January and February. Potential links with
an inﬂuenza A outbreak were not tested in this study.
Clinical, radiological and biological data
Patients with PVL-MSSA necrotizing pneumonia were signiﬁ-
cantly more likely to have multiple sites of S. aureus infection
at the time of admission (25.2% versus 6.9%, p 0.039). Air-
way haemorrhage tended to be more typically associated
with PVL-MSSA (44.2% versus 24.1%; p 0.056). There were
no additional statistical differences in clinical or biological
data. The radiological ﬁndings at the time of admission indi-
cated equally severe disease.
Multivariate analysis
The multivariate analysis identiﬁed airway haemorrhage as
the only factor negatively associated with PVL-MRSA CAP
(adjusted OR 0.32; p 0.028).
Management
Admission to the ICU occurred in 82 PVL-MSSA cases
(79.6%) and 20 PVL-MRSA cases (69.0%). There were no dif-
ferences in the severity scores. Of all cases, 64% required
mechanical ventilation (66.3% for PVL-MSSA and 55.2% for
PVL-MRSA cases, p 0.797). Of these, 85.5% of PVL-MSSA
and 87.5% of PVL-MRSA received inotrope support
(p 0.527). Appropriate empirical antibiotic therapy, which
consisted of at least one antibiotic that is active in vitro on
the particular S. aureus strain, was initiated during the ﬁrst
24 h of hospitalization in 86% of all cases (87.8% of CA-
MSSA and 79.2% of CA-MRSA, p 0.324). Drug dosage and
combination therapy were not recorded.
Antibiotics with antitoxinic properties (i.e. linezolid, clinda-
mycin or rifampicin) were used in 33 patients of 98 (33.7%)
but these particular data were missing in 32 cases. In most
cases, these treatments were used as a second-line therapy,
after the ﬁrst 24 hours. Polyvalent intravenous immunoglob-
ulins were employed twice and both patients survived.
Survival analysis
There were no differences in mortality between PVL-MSSA
and PVL-MRSA cases (39.4% versus 37.9%, respectively;
p 0.884). For the deceased patient, median survival times
were 1.0 day and 0.5 day for PVL-MSSA and PVL-MRSA
cases, respectively (p 0.234). The duration of hospitalization
(24 days for PVL-MSSA versus 24 days for PVL-MRSA;
p 0.403) and ICU stay (17 days for PVL-MSSA versus 16 days
for PVL-MRSA; p 0.985) for survivors were similar.
There were no differences in the cumulative survival rates
by log-rank test (p 0.877 and p 0.892 for 7-day and 30-day
survival, respectively) (Fig. 1). Cox univariate analysis con-
ﬁrmed that methicillin resistance was not a signiﬁcant predic-
tor of mortality at 7 days or at 30 days (hazard ratio (HR)
1.29 p 0.656 and HR 1.19 p 0.711, respectively). On univari-
ate analysis, airway bleeding was strongly associated with a
fatal outcome (HR 3.75 p <0.001 and HR 3.68 p <0.001 for
7-day and 30-day mortality, respectively). Mortality reached
65% in cases with haemoptysis versus 23% in those without
(p <0.001). Leucocyte counts were negatively correlated
with mortality, as mortality occurred in 75% of cases with
leukopenia (<3000 leucocytes/mL), in 26% of cases with leu-
cocyte counts between 3000/mL and 10 000/mL and in 8%
of cases with leucocyte counts >10 000/mL. The use of an
antitoxinic treatment was associated with a better outcome
(mortality rate 6.1% versus 52.3%, p <0.001): association
with a skin and soft-tissue infection was associated with
decreased mortality (mortality rate of 16%; p 0.006). The
model was adjusted on severity (as deﬁned above) and pres-
ence of mecA gene. Cox multivariate analysis showed that
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airway haemorrhage, leukopenia and absence of antitoxinic
treatment were risk factors for 30-day mortality (Table 2).
Discussion
Staphylococcal NP was individualized for both MSSA and
MRSA in 2002 and was associated with the production of
PVL [1]. NP represents only a small fraction of staphylococ-
cal CAP, and some confusion has attended efforts to
distinguish between methicillin resistance and other severity-
associated factors, especially in studies focusing on MRSA
CAP. In a retrospective review of staphylococcal, PVL-posi-
tive CAP, Vardakas et al. [20] found 71 articles that reported
data from 107 cases between 1985 and 2008, and most of
these cases were individual case reports. Our study reports
TABLE 1. Characteristics and outcome of community-acquired, Panton–Valentine-positive, methicillin-resistant and methicil-
lin-susceptible Staphylococcus aureus necrotizing pneumonia in a French cohort of 133 patients from 1986 to 2010
Characteristic CA-MSSA (n = 104) CA-MRSA (n = 29) Univariate OR (95% CI) p-valuea
Demographics
Age (years) 22 (4.5–43.7) 22.5 (0.7–46.5) 0.99 (0.98–1.01) 0.717
Male gender 64 (61.5) 17 (58.6) 1.29 (0.49–2.61) 0.831
Comorbid condition
No underlying diseaseb 92 (88.5) 22 (75.9) 2.51 (0.82–7.64) 0.111
Personal or familial history of skin and soft-tissue infectionc 18 (24.0) 4 (18.2) 0.70 (0.21–2.35) 0.773
Symptoms before hospitalization
Time from onset of symptoms to hospital admission (days) 3.0 (2.00–5.00) 3.5 (2.25–5.75) 1.01 (0.90–1.13) 0.847
Inﬂuenza-like syndrome 61 (59.8) 19 (65.5) 1.27 (0.54–3.02) 0.669
Skin and soft-tissue infectiond 28 (26.9) 3 (10.3) 0.31 (0.09–1.12) 0.082
Clinical symptoms during the ﬁrst 24 h of hospitalizatione
Fever >39C or temperature <36C 83 (79.8) 21 (72.4) 0.66 (0.26–1.71) 0.447
Airway haemorrhagef 46 (44.2) 7 (24.1) 0.40 (0.16–1.02) 0.056
Additional focus of staphylococcal infectiong 26 (25.2) 2 (6.9) 0.22 (0.05–0.99) 0.039
Radiological ﬁndings during the ﬁrst 24 h of hospitalizationh
Pleural effusion 16 (55.2) 13 (44.8) 1.09 (0.47–2.50) 0.836
Multilobar consolidation 67 (65.7) 15 (51.7) 0.56 (0.24–1.29) 0.195
Biological ﬁndings during the ﬁrst 48 h of hospitalization
Lowest leucocyte count (109/L) 5.5 (1.4–14.6) 4.7 (1.2–11.8) 1.00 (0.99–1.01) 0.586
Categorical leuxcocyte count
<3000 leucocytes/mL 38 (36.9) 13 (44.8) 0.580
3000–10 000 leucocytes/mL 26 (25.2) 8 (27.6)
>10 000 leucocytes/mL 39 (37.9) 8 (27.6)
Lowest platelet count (109/L) 171 (92–275) 164 74–275) 1.00 (0.99–1.01) 0.767
ICU admissione,i 82 (79.6) 20 (69.0) 0.57 (0.23–1.43) 0.315
Severity markers
PRISM score (n/N) 18 (12–35) 18/32 11 (5–31) 6/9 0.95 (0.89–1.02) 0.217
SAPS II score (n/N) 57 (27–78) 44/50 64 (39–89) 11/11 0.99 (0.97–1.01) 0.436
PaO2/FiO2 ratio (n/N) 70 (50–105) 49/82 67 (50–99) 10/20 1.00 (0.99–1.01) 0.968
Therapy
Mechanical ventilation 69 (66.3) 16 (55.2) 0.62 (0.27–1.44) 0.282
Duration of mechanical ventilation (days) 2.0 (1.0–14.0) 3.5 (1.0–11.7) 0.797
Inotrope support 59 (56.7) 14 (48.3) 0.71 (0.31–1.62) 0.527
Appropriate antibiotic therapy in the ﬁrst 24 h of hospitalizationj 86 (87.8) 19 (79.2) 0.53 (0.17–1.68) 0.324
Outcome
Complicationsk 85 (81.7) 23 (79.3) 0.86 (0.31–2.39) 0.790
ARDS 48 (46.2) 10 (34.5) 0.61 (0.26–1.45) 0.296
Mortality 41 (39.4) 11 (37.9) 1.06 (0.46–2.48) 0.884
Time to death (days) 1.0 (0.5–3.7) 0.5 (0.5–3.0) 0.234
Duration of survivor hospitalization (days) 24 (17–41) 24 (14–32) 0.403
OR, odds ratio; ICU, intensive care unit; PRISM, Paediatric Risk of Mortality; SAPS II, Simpliﬁed Acute Physiology Score II; ARDS, acute respiratory distress syndrome; CA-
MRSA, community-acquired, methicillin-resistant Staphylococcus aureus; CA-MSSA, community-acquired, methicillin-susceptible Staphylococcus aureus; SSTI, skin and soft-tissue
infection.
Data represent the number (%) of patients for categorical variables and the median (interquartile range) for continuous variables.
aFisher’s exact test for categorical variables, except for categorical leucocytes (Pearson’s chi-square test); Kruskal–Wallis test for continuous variables.
bUnderlying diseases included diabetes mellitus (four cases of CA-MSSA and three cases of CA-MRSA), chronic respiratory insufﬁciency (two cases and one case, respec-
tively), corticosteroid use (four cases and four cases, respectively) and immunosuppressive therapy (ﬁve cases and three cases, respectively).
cData were available for 90 patients and included those with a personal history of SSTI (10 cases of CA-MSSA and one case of CA-MRSA) and familial history of SSTI (eight
cases and three cases, respectively).
dSSTIs included cutaneous abscesses in 11 cases of CA-MSSA infection, furuncles in nine cases of CA-MSSA and two cases of CA-MRSA and both superﬁcial SSTI and cutane-
ous abscess in eight cases and one case, respectively.
eData were collected for 119 patients, because one patient died before admission.
fAirway haemorrhages included lower airway haemorrhage in three cases, upper airway haemorrhage in 33 cases and both lower and upper airway haemorrhage in nine
cases. All seven CA-MRSA cases involved upper airway haemorrhage.
gOther types of infection included pyomyositis, arthritis, spondylodiscitis, uveitis and sinusitis.
hData were collected for 118 patients due to rapid patient death after admission.
iUpon hospitalization, ICU admission occurred in 57 cases of CA-MSSA and 18 cases of CA-MRSA, and secondary ICU admission occurred in 25 cases and two cases,
respectively.
jData were collected for 111 patients due to rapid patient death after admission and before antibiotic administration.
kComplications included septic shock, pyothorax, pneumothorax, empyema, septic myocarditis, pericarditis, osteomyelitis, epidural abscess, hepatic abscess, renal abscess,
septic thrombophlebitis, septic retinitis and bronchiectasis.
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the results of a prospective surveillance study of 133 PVL-
positive staphylococcal necrotizing CAP cases that occurred
in France between 1986 and 2010.
In this study, we found no differences between PVL-
MRSA and PVL-MSSA CAP in terms of severity or outcome.
Multivariate analysis revealed that airway haemorrhage,
which was strongly associated with lethality in previous
studies, was more likely to be associated with PVL-MSSA
pneumonia than PVL-MRSA pneumonia. No other factor
was associated with methicillin susceptibility, which indicated
that MSSA and MRSA NP were clinically and biologically
indistinguishable.
In vitro theoretically appropriate empirical antibiotic ther-
apy was initiated during the ﬁrst 24 h of hospitalization in
87.8% of PVL-MSSA cases and 79.2% of PVL-MRSA cases
(p 0.324), and there were no differences in ICU admission,
mechanical ventilation or inotrope support between the
groups. Hence, differences in the initial management of the
infection could not have interfered with severity.
Our choice to restrict the case deﬁnition to PVL-associ-
ated strains allowed a more accurate comparison of
CA-MSSA and CA-MRSA. In the literature, the only variables
signiﬁcantly associated with CA-MRSA infection were risk
factors for the acquisition of CA-MRSA carriage, such as
crowding, skin-to-skin contact and a lack of personal cleanli-
ness and hygiene [21,22]. Experimental studies have sug-
gested that CA-MRSA (particularly the USA300 lineages) is
especially virulent, as a result of the successful combination
of the full arginine catabolic mobile elementACME element
and an SCCmec element [23]. Conversely, others studies
have tended to emphasize the role of PVL in the virulence of
CA-MRSA [15,16]. In the present study, we ought to neu-
tralize the effect of PVL by selecting only cases of PVL-posi-
tive NP. We cannot rule out the possibility that PVL-MRSA
and PVL-MSSA of our series harbour different isoforms of
PVL as described previously [24] or different expression
levels of PVL and other virulence factors [25] even though
PVL concentrations in vivo might not be different between
PVL-MRSA and PVL-MSSA, as observed for human abscesses
[26]. However, given the lack of differences in outcome of
the two series, we are conﬁdent in the conclusion that resis-
tance to methicillin per se does not impact virulence of
PVL-positive strains, at least in the context of French epide-
miology where PVL-MRSA mostly belong to the ST80 lineage
[27]. Indeed this is not always the case as other studies
revealed that certain SCCmec elements, especially those
present in hospital-acquired MRSA, can affect the overall vir-
ulence by modulating core-genome encoded virulence factors
[28].
This analysis of 133 cases has conﬁrmed the overall sever-
ity of S. aureus necrotizing CAP. Cases of NP occurred lar-
gely in young people; the median age was 22 years, which
was only slightly higher than had been previously reported
[1,29]. Although lower than initially reported, lethality
remained high (39%) considering the patients’ youth and lack
of underlying conditions. Initial presentation with airway
bleeding and leukopenia were associated with a fatal out-
come and appear to be speciﬁcally related to this disease. As
previously described, we observed a trend for S. aureus NP
to occur during winter seasons, probably because of the rec-
ognized link between S. aureus pneumonia and viral respira-
tory infections, especially inﬂuenza [30]. Nevertheless, the
number of cases with a deﬁnite viral diagnosis was too low
to permit any conclusions.
In our study, 86% of patients received antibiotics consid-
ered as appropriate during the ﬁrst 24 h of hospitalization.
However, mortality remained high, which suggested that this
treatment was not optimal. Clinical data suggest that the
inhibition of bacterial toxin production can improve the out-
come of infection [31,32]. As we have demonstrated the
persistence of high mortality despite theoretically appropri-
ate antibiotics, this study suggests that considerations about
FIG. 1. Kaplan–Meier survival curves after 30 days for patients with
community-acquired, Panton–Valentine-positive, Staphylococcus aureus
necrotizing pneumonia according to methicillin susceptibility.
TABLE 2. Cox regression analysis of factors associated with
30 days mortality in community-acquired, Panton–Valentine
leukocidin-positive Staphylococcus aureus necrotizing pneu-
moniaa
Variable p-value
Multivariate adjusted
hazard ratio (95% CI)
Airway haemorrhage 0.004 2.96 (1.41–6.25)
Leucocyte count (109/L)b 0.001 0.32 (0.17–0.61)
Antitoxinic treatment 0.002 0.11 (0.03–0.49)
aThe model was adjusted on severity and presence of the mecA gene.
bIn this model, natural logarithms of leucocyte counts were used.
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the management of staphylococcal NP should not be based
solely on antibiotic susceptibility. Several important staphylo-
coccal toxins, including PVL, are over-expressed in the pres-
ence of b-lactams, but their expression can be blocked by
the combined use of a toxin-suppressing agent (e.g. clindamy-
cin, linezolid or rifampin) with antibiotics that target the cell
wall [33,34]. In addition, intravenous immunoglobulins can
neutralize the lytic effect of PVL on polymorphonuclear cells
in vitro [35]. The use of antitoxinic treatment was indepen-
dently associated with a better outcome in our study. How-
ever, there were important variations between patients,
especially in the time of introduction, which limits the inter-
pretation of this result. Nevertheless, the potential beneﬁts
of such treatments that target toxin production have been
recently emphasized in a retrospective study [36] and may
be a promising method to improve the outcome of both
MRSA and MSSA NP.
The present investigation had certain limitations. First,
case reporting to the Reference Centre was unsolicited and
may not have reﬂected accurate data on the epidemiology
and severity of this disease, as severe cases in previously
healthy young people and those caused by methicillin-resis-
tant strains are more likely to have been reported. Hence,
our result does not reﬂect the evolution of the true inci-
dence of PVL-MRSA in France but only the trend for cases
reported to the Reference Centre. A second limitation con-
cerns the clinical data collection. The analysis of trends over
time included 161 cases for which microbiological and
demographic data were available, but 28 cases (20 PVL-
MSSA and 8 PVL-MRSA) were excluded from further analy-
ses because they lacked at least one important data point.
However, comparisons between the 28 excluded cases and
the 133 analysed cases revealed no differences in mortality
or in the percentage of MRSA. Third, as the data were col-
lected over an extended time period, there may have been
signiﬁcant changes in the epidemiology or in the general
knowledge of the disease over time that could have inﬂu-
enced our results. Nevertheless, beside the increase in
observed PVL-MRSA frequencies during the study period,
no signiﬁcant changes concerning other data were observed
over time.
In conclusion, this report emphasizes that S. aureus NP
remains an extremely severe disease regardless of methicillin
resistance. We found no reliable demographic or clinical fac-
tor that could distinguish patients with CA-MRSA pneumonia
from those with CA-MSSA pneumonia. We also report that
CA-MRSA is an increasing cause of severe CAP in France,
which supports the use of anti-MRSA antibiotics for severe
pneumonia when clinical and biological features suggest
staphylococcal NP.
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Key points
The absence of a relationship between disease severity and
methicillin resistance in Staphylococcus aureus necrotizing
pneumonia was demonstrated as well as the persistence of
high mortality, despite the signiﬁcant body of knowledge on
this disease.
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